Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,463 total articles

Zscaler Collaborates with IBM and Red Hat to Protect Private Applications from Frontier AI-Powered Threats

Zscaler Collaborates with IBM and Red Hat to Protect Private Applications from Frontier AI-Powered Threats

Zscaler announced a collaboration with IBM and Red Hat to enhance protection of private applications by combining Zscaler's Autonomous Application Shield with IBM and Red Hat's Lightwell platform. This partnership aims to bridge the critical vulnerability window between disclosure and patch deployment by providing adaptive, inline security that ope…

Osisko Gold Intersects 7.28 g/t Au over 16.15 m (105 m Vertical Depth), including 173.66 g/t Au over 0.60 m, and 7.13 g/t Au over 11.60 m (61 m Vertical Depth) in Lowhee Zone Underground Infill Drilling at Cariboo Gold Project

Osisko Gold Intersects 7.28 g/t Au over 16.15 m (105 m Vertical Depth), including 173.66 g/t Au over 0.60 m, and 7.13 g/t Au over 11.60 m (61 m Vertical Depth) in Lowhee Zone Underground Infill Drilling at Cariboo Gold Project

Osisko Gold Group Inc. announced significant gold assay results from 3,933 meters of underground infill drilling in 36 holes at the Lowhee Zone of its Cariboo Gold Project in British Columbia, Canada. Highlight intersections include 7.28 g/t Au over 16.15m and 7.13 g/t Au over 11.60m. These results reinforce confidence in the resource potential, su…

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This product represents the company's first fully synthetic device developed and manufactured in-house at their Malvern facility. The clearance is expected to broaden TELA Bio’s presence in the soft tissue rec…

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Prime Medicine has initiated dosing in its global Phase 1/2 clinical trial of PM577a, an in vivo Prime Editing therapy aimed at correcting the H1069Q mutation causing Wilson disease. This one-time gene editing treatment is designed to address the genetic root of Wilson disease, a rare progressive disorder lacking curative therapies. The U.S. FDA ha…

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

vTv Therapeutics has completed enrollment of 166 patients in its Phase 3 CATT1 study evaluating cadisegliatin, a novel oral glucokinase activator with Breakthrough Therapy designation, aimed at reducing hypoglycemia and improving glycemic control in type 1 diabetes patients. Topline results are expected in mid-2027, advancing cadisegliatin towards …

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

Pacira BioSciences announced an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL, its non-opioid long-acting local analgesic for postsurgical pain, across the European Union and United Kingdom. This strategic partnership aligns with Pacira's 5x30 growth strategy, aims to enhance patient access to opioid-sparing therapies, and …

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Lisata Therapeutics, through its subsidiary Marea Therapeutics, has dosed the first patient in a Phase 2 clinical trial for MAR002, a novel monoclonal antibody designed to treat acromegaly by blocking growth hormone receptors. The therapy demonstrated promising Phase 1 results with durable IGF-1 suppression and potentially infrequent dosing compare…

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Celcuity Inc. announced it will present new clinical trial data at the European Society for Medical Oncology (ESMO) Congress 2026. The presentations will cover updated results from the VIKTORIA-1 Phase 3 trial of gedatolisib in hormone receptor positive, HER2-negative advanced breast cancer and findings from trials in metastatic castration-resistan…

MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network

MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network

MindWave Innovations Inc. USA, a subsidiary of Apimeds Pharmaceuticals US (NYSE American: APUS), signed a 2-year master maintenance and service agreement with BlockAssure Inc. to develop, deploy and operate AssureChain, a dedicated blockchain subnet for insurance and reinsurance operations. The contract includes development fees and a 20% allocatio…

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Radiopharm Theranostics successfully completed an End-of-Phase 2 meeting with the FDA regarding RAD101, a novel imaging agent targeting fatty acid synthase for detecting brain metastases. The productive interaction clarified the regulatory pathway, enabling the company to proceed with Phase 3 clinical trial preparations. The FDA's feedback is expec…

Trasteel Holding S.A., Through Newly Established Trasteel Magona, Takes Over Operations of La Magona d’Italia Steel Plant in Piombino, Italy

Trasteel Holding S.A., Through Newly Established Trasteel Magona, Takes Over Operations of La Magona d’Italia Steel Plant in Piombino, Italy

Trasteel Holding S.A., a global steel trading and industrial group, has assumed operational control of the La Magona d’Italia steel plant in Piombino, Italy, through newly formed Trasteel Magona S.r.l. The plant, operating under a lease agreement until the end of 2027, will be gradually restarted with a goal to reach full production capacity of ove…

4DMT to Host Investor Day on October 21, 2026

4DMT to Host Investor Day on October 21, 2026

4D Molecular Therapeutics announced it will host an Investor Day on October 21, 2026, in New York City, featuring presentations and discussions with leading retinal experts. The event will highlight advancements in the company's lead product candidate 4D-150, a durable therapy targeting VEGF-driven retinal vascular diseases like wet age-related mac…

Polyrizon Files for U.S. Patent Application to Expand IP Moat  Around Intranasal Drug-Delivery Platform

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Ltd., a clinical-stage biotech specializing in intranasal hydrogels, has filed a new U.S. divisional patent application to further protect its proprietary mucoadhesive polymer technology. This technology underpins the company's nasal drug delivery platform, potentially enabling local and systemic delivery of therapeutic agents via nasal m…

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

BridgeBio Pharma announced new 12-month interim data from its Phase 3 FORTIFY trial demonstrating that BBP-418, an oral therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), significantly improves cardiac biomarkers such as high-sensitivity troponin I and left ventricular ejection fraction. The therapy increased glycosylated alpha-dyst…

Nexus Advanced Technologies Announces Anson Note and Warrant Restructuring Agreement with Anson Funds

Nexus Advanced Technologies Announces Anson Note and Warrant Restructuring Agreement with Anson Funds

Nexus Advanced Technologies Inc. announced an agreement with Anson Funds to restructure convertible notes and warrants. This agreement aims to simplify the company's capital structure by fixing conversion prices, eliminating anti-dilution provisions, and enabling a warrant exchange that will dilute existing shareholders but retire adjustment provis…

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Crescent Biopharma announced FDA clearance of the IND application for CR-002, a topoisomerase inhibitor antibody-drug conjugate targeting PD-L1, intended to treat advanced solid tumors. The company plans to launch the global Phase 1/2 APOLLO trial in Q4 2026, enrolling approximately 200 patients with various solid tumors such as NSCLC and HNSCC, wi…

Jiuzi Holdings’ AI Smart Imaging Platform Accelerates Toward Completion: Enterprise-Grade Solution Nears Commercialization; Million-Dollar Profit Expectation Opens New Growth Space

Jiuzi Holdings’ AI Smart Imaging Platform Accelerates Toward Completion: Enterprise-Grade Solution Nears Commercialization; Million-Dollar Profit Expectation Opens New Growth Space

Jiuzi Holdings, Inc. (NASDAQ: JZXN) announced significant progress on its AI smart imaging and data platform, evolving it into an enterprise-grade, modular, and scalable solution targeting smart retail, intelligent security, media content management, and advanced driver assistance applications. The company anticipates approximately $1.55 million in…